Sponsored by
The findings of this study are highly remarkable. Even in patients with IDH wild-type glioblastoma and unmethylated MGMT, which typically indicates a poorer prognosis, the five-year survival rate reached an encouraging 33%. It is important to note that these results are based on early-stage research with a limited number of patients, so it is necessary to exercise caution before drawing definitive conclusions. Nevertheless, this study holds significant potential, and I will certainly monitor its progress closely.